

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



SYMPOSIUM

ACCESSIBILITY & IMPACT OF HIGH VALUE MEDICINES

SCIENCE, PATIENTS, POLITICS

ORGANISATION: LA RISK RESEARCH LLP

A UNIQUE FORUM WHERE ADVANCED SCIENTISTS, HEALTH AUTHORITIES,
PATIENT ADVOCATES & INDUSTRY DECISION-MAKERS CONFRONT THEIR
IDEAS ON HOW TO ENSURE BETTER ACCESS TO HIGH VALUE MEDICINES
WHILE PROPERLY ASSESSING THEIR IMPACT

SATELLITE SCIENTIFIC WORKSHOP

REAL WORLD EVIDENCE ON THE IMPACT OF MEDICINES

15 JANUARY 2019

13:30-18:00

- Measures of impact of medicines in the real life: are methods adapted?
- How to accelerate access to important medicines by the right mix of pre-marketing / post-marketing studies?
- How to do pharmacoepidemiologic research with a real clinical and public health impact?
- What research is useful for Decision-Making?
- UK, France & Italy coverage with evidence development polices: what went wrong (and well)?
- Can RCT + Modelling Replace Observational Studies?

SYMPOSIUM

SCIENCE, PATIENTS AND THE POLITICS OF ACCESS TO HIGH VALUE MEDICINES

16 JANUARY 2019

09:00-18:00

- The International, the European, the Central European challenges at a time of change
- Is Brexit going to complicate or simplify the issues in Europe?
- Are present HTA models adapted to high value innovation?
- At what cost can we afford innovations? Will new economic models solve it all?
- Industry approach to high value medicines: Thinking Globally and Acting Locally? Or else?
- Access to High Value Medicines: a Human Right?
- Does the American "Patient First" call apply to Europe?
- Rare diseases, cancer: same struggle?

Registration and more information at:

www.accessibility-symposium.org

ACCESSIBILITY & IMPACT OF HIGH VALUE MEDICINES

SCIENCE, PATIENTS, POLITICS

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



SYMPOSIUM CO-CHAIRS



PROF. PETER PIOT
Director, London School of
Hygiene & Tropical Medicine,
Former Head, UNAIDS



PROF. LUCIEN ABENHAIM
Hon. Prof. LSHTM
LA Risk Research
Fmr Board Member, WHO

SPEAKERS AND PANELISTS

- HEALTH AUTHORITIES FROM NICE, HAS, G-BA, CEE COUNTRIES, THE EUROPEAN COMMISSION AND WHO
- PATIENT ADVOCATES
- INDUSTRY DECISION-MAKERS
- LEADERS IN HEALTH LAW & GOVERNANCE, PHARMACO-ECONOMICS & PHARMACO-EPIDEMIOLOGY

REAL WORLD EVIDENCE WORKSHOP 15 JANUARY 2019



PROF. STEPHEN EVANS
London School of
Hygiene & Tropical
Medicine, UK



PROF. MIRIAM STURKENBOOM
Utrecht Medical
Center, The
Netherlands



PROF. BERNARD BEGAUD
University of
Bordeaux, France



PROF. SEBASTIAN SCHNEEWEISS
Harvard Medical
School & T.H.Chan
School of Public Health



DR. BILLY AMZAL
Chief Ing. X-Ponts,
France, SVP Decision
Analytics Analytica
Certara



PROF. MAHMOUD ZUREIK
UVSQ & ANSM
France



PROF. LAMIAE GRIMALDI
UVSQ, APHP
Paris France



PROF. LIAM SMEETH
London School of
Hygiene & Tropical
Medicine, UK

SYMPOSIUM 16 JANUARY 2019

HEALTH AUTHORITIES



PROF. DOMINIQUE LE GULUEC
President, Higher
Health Authority
(HAS), France



SIR ANDREW DILLON
Chief Executive,
NICE, UK



DR. ANDRZEJ RYS
Director for Health
Systems, Medical, Prod.
& Innovation
European Commission.



DR. SARAH GARNER
Coordinator Innovation,
Access and Use,
Essential Med. &
Health Products, WHO



DR. MIRJANA HUIC
Agency Quality and
Accreditation in Health
Care and Social Welfare
Croatia



DR. ANTJE BEHRING
Acting Head of
Pharmaceuticals Department
(AMNOG), Federal Joint
Committee (G-BA).

INDUSTRY DECISION MAKERS



DR. STEFAN OSCHMANN
•President EFPIA
•CEO Merck Group


Keynote Speaker



DR. PATRICE MATCHABA
Group Head Global
Health & Corp.
Responsibility, Novartis



DR. ANNALISA JENKINS
CEO PlaqueTec



DR. THOMAS LYNCH
CSO & Exec
VP R&D, BMS



DR. MICHAEL DEVOY
CMO
Bayer HealthCare



DR. ROB SCOTT
CMO & VP
Development
AbbVie



DR. JENS GRUEGER
SVP Head of Global
Access, Roche



DR. CLAUDIUS RUNGE
SVP Global
Market Access
Bayer Health Care

PHARMACOECONOMISTS & EXPERTS



PROF. GÉRARD DE POUVRVILLE
ESSEC Business
School, France



PROF. MARTIN MCKEE
London School of
Hygiene & Tropical
Medicine, UK



PROF. RON AKEHURST
University of
Sheffield, UK



PROF. GORIK OOMS
Global Health Law &
Governance, London
School of Hygiene
& Tropical Medicine



YANN LE CAM
Chief Executive,
EURORDIS,
Rare Diseases Europe

PATIENT ADVOCATES

Registration and more information at:

www.accessibility-symposium.org

PROGRAMME OF THE SATELLITE WORKSHOP
EVIDENCES OF THE IMPACT OF ACCESS

TUESDAY 15 JANUARY 2019
(THE DAY BEFORE THE
SYMPOSIUM)

13:00	Registration, Tea and Coffee
	Workshop Chair: <i>Prof. Stephen Evans, LSHTM</i> Objectives of the Workshop: <i>Prof. Lucien Abenheim, LSHTM</i>
First Part: Relevant Methods for Access Impact Assessment	
13:30	How can observational studies reproduce causality assessment – Results of a FDA-Harvard Research Programme <i>Prof. Sebastian Schneeweiss, Harvard Medical School & T.C. Chan School of Public Health</i> Can impact assessment be reliably predicted? <i>Dr. Billy Amzal, X-Ponts & Analytica Certara</i> Panel discussion: Introduction by Bernard Begaud (University of Bordeaux) Causality, biases and decision: when is enough enough?
15:30	<i>Break</i>
Second Part: Case-Studies on Public Health Impact of Recent Medicines & Vaccines	
15:45	Chair: <i>Prof. Liam Smeeth, Bernard Begaud (University of Bordeaux)</i> Results of research on the public health impact of medicines Impact of Maternal Immunization and Monitoring of Safety <i>Prof. Miriam Sturkenboom* Utrecht Medical Center, The Netherlands</i> Vaccines and auto-immune disorders: review and results <i>Prof. Lamiae Grimaldi, University of Paris-Versailles SQY</i> Vaccines: From Perception to Action <i>Prof. Heidi Larson, London School of Hygiene & Tropical Medicine</i> Observational studies and regulatory decisions: ANSM experience <i>Prof Mahmoud Zureik (Université Versailles St-Quentin & Agence Nationale de Sécurité des Médicaments (ANSM), France</i>
17:00	Panel: Is a Scientific Forum on the Public Health Impact Assessment of Medicines Needed? <i>All Workshop Attendees</i>
17:45	Conclusions and Recommendations for the Policy Session
18:00	<i>Workshop Closure</i>

LIMITED SEATS ARE AVAILABLE AT THE WORKSHOP

Registration and more information at:
www.accessibility-symposium.org

SEE PROGRAMME OF THE SYMPOSIUM
POLICY SESSION

PROGRAMME OF THE SYMPOSIUM
ACCESSIBILITY & IMPACT OF HIGH VALUE MEDICINES
SCIENCE, PATIENTS, POLITICS

WEDNESDAY
16 JANUARY 2019

SESSION 1 : EUROPE AMONGST WORLD CHALLENGES

- 9:00** Welcome, Objectives & Orientations
Prof. Lucien Abenhaim, LSHTM & LARR, Symposium Co-Chair
- The Road to Access
Prof. Peter Piot, Director, London School of Hygiene & Tropical Medicine Symposium Co-Chair
 - Worldwide Situation of Access to Medicines
Dr. Sarah Garner, Coordinator Innovation, Access & Use, Essential Medicines, WHO
 - Access to High Value Medicines: European Union Policy at a Time of Change
Dr. Andrzej Rys, Director, Health Systems, European Commission
 - Access to High Value Medicines in the UK at a Time of Change
Sir Andrew Dillon, Chief Executive, NICE
 - For a new policy on innovative Medicines in Europe: Recent Report to EC
Prof. Martin McKee, LSHTM

10:40 Morning Break

- 11:00** **Keynote Address:** Access to Medicines: Industry Proposals at a Time of Change
Dr. Stefan Oschmann, President, EFPIA (European Federation of Pharmaceutical Industry Associations) and CEO, Merck Group

Panel discussion: Brexit and World Challenges

All speakers of the morning session and Dr. Patrice Matchaba (Novartis)

12:30 Lunch

13:45 **SESSION 2 : THE SCIENCES OF ACCESS IN EUROPE**

- HAS Assessment Methodology: What's New?
Prof. Dominique Le Guludec, HAS (Haute Autorité de Santé, France)
- NICE Highly Specialized Technologies Committee's Methods
Prof. Ron Akehurst, Health Economist, SchARR, University of Sheffield
- Access to High Value Medicine in Germany: The G-BA Method Revisited
Dr. Antje Behring, Acting Head of Pharmaceuticals Department, AMNOG.
- Making High Value Medicines Available in the CEE: a Survey of Multiple CEE Countries
Dr. Mirjana Huic, Agency Quality and Accreditation in Health Care and Social Welfare Croatia
- HTA & Pricing: Is There One Solution to the Challenge?
Prof. Gerard de Pouvourville, ESSEC Business School

Report from the Satellite Workshop: Reliably Measuring Access Impact in the Real Life, Now.

Prof. Stephen Evans (LSHTM) & **Prof. Sebastian Schneeweiss** (Harvard Medical School)

- 15:30** **Panel discussion: Are Solutions for Access More Converging or Diverging in Europe?**
All speakers of the session and Dr. Rob Scott (AbbVie) & Dr. Michael Devoy (Bayer)

16:00 Afternoon Break

SESSION 3 : PANEL CASE STUDIES : HURDLES & SOLUTIONS FOR ACCESS IN PRACTICE

- 16:15**
- Access to Rare Diseases Medicines. **Yann Le Cam** (EURORDIS)
 - Evaluation of New Cancer Treatments for Access.
 - The "American Patients First" Blueprint and Europe. **Dr. Jens Grueger** (Roche)
 - Development of accessible tests and devices. **Dr. Annalisa Jenkins** (PlaqueTec)

Panel discussion: General Policies or Myriad of Problem-Specific Solutions?

All Speakers of the Panel and Dr. Thomas Lynch (BMS) and Dr. Claus Runge (Bayer),

- 17:30** **Closing Conference: Global Health Governance and Access to Medicines as a Human Right**
Prof. Gorik Ooms, London School of Hygiene & Tropical Medicine

18:00 **Symposium Closure and Networking Reception**

SYMPOSIUM REGISTRATION & LOGISTICS

The workshop will be held at the London School of Hygiene & Tropical Medicine and allows limited seating (40)

The SYMPOSIUM is at the LONDON SAINT-PANCRAS RENAISSANCE HOTEL

MORE INFORMATION AND REGISTRATION AT: www.accessibility-symposium.org

FEES FOR THE SYMPOSIUM

REGULAR FEES : £499 + VAT

ACADEMIA & PUBLIC AGENCIES : £199 + VAT

CONSULTING & SERVICE COMPANIES £1200 + VAT

REGISTRATION TO THE WORKSHOP IS UPON REQUEST

Fees include welcome tea & coffee, breaks, lunch.

Fees do not include accommodations Special rates are available for the Saint-Pancras Renaissance Hotel. A list of nearby hotels with varying rates is available upon request.

No profits are drawn from the Workshop and Symposium

Registration and more information at:

www.accessibility-symposium.org

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



ORGANISATION: LA RISK RESEARCH LLP
1-10, SUMMERS ST, SUITE # 1,
LONDON EC1R 5BD, UK

Contact: l.abenhaim@la-risk.com,
adam.levy@lshtm.ac.uk